Glenmark Pharmaceuticals Limited
NSE: GLENMARK BSE: GLENMARK
NSE
2,132.50
4.80 (0.23%)
Prev Close
2127.7
Open Price
2128
Volume
615,366
Today Low / High
2117.3 / 2156.9
52 WK Low / High
1275.5 / 2284.8
Range
2,026 - 2,239
BSE
2,130.70
3.70 (0.17%)
Prev Close
2127
Open Price
2149.95
Volume
7,973
Today Low / High
2118.95 / 2156.75
52 WK Low / High
1274.7 / 2286.15
Range
2,024 - 2,237
The stock is currently trading on both the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE). On the NSE, the stock is priced at 2132.5 (target range: 2,026 - 2,239), reflecting a change of 4.8 (0.2256%). On the BSE, it is listed at 2130.7 (target range: 2,024 - 2,237), showing a change of 3.7 (0.17395%). Both the NSE and BSE data indicate positive movement, suggesting the stock is on an upward trend. This could be an attractive opportunity for investors looking for growth.
12 Sep
2,128.00
0.21%
11 Sep
2,132.50
-0.23%
10 Sep
2,112.00
0.89%
09 Sep
2,073.00
2.09%
08 Sep
2,062.00
-0.49%
05 Sep
1,990.90
3.06%
04 Sep
2,025.00
-1.68%
03 Sep
1,938.00
3.43%
02 Sep
1,926.90
-0.42%
01 Sep
1,918.10
0.45%
29 Aug
1,936.00
-0.62%
28 Aug
1,957.90
-1.07%
26 Aug
1,956.50
-0.30%
25 Aug
1,940.90
0.78%
22 Aug
1,940.90
-0.19%
21 Aug
1,924.00
0.88%
20 Aug
1,949.00
-1.28%
19 Aug
1,975.00
-1.48%
18 Aug
2,009.90
-1.79%
Glenmark Pharmaceuticals Limited Graph
Glenmark Pharmaceuticals Limited Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges
If you are looking for the target price for Glenmark Pharmaceuticals Limited T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 2,132.50, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.
| Scenario | Price | Target | Range |
|---|---|---|---|
| Bullish Scenario | 2,130.70 | 2,152.01 | 1,936.81 - 2,367.21 |
| 2,173.31 | 1,738.65 - 2,607.98 | ||
| 2,194.62 | 1,536.23 - 2,853.01 | ||
| Bearish Scenario | 2,130.70 | 2,109.39 | 1,898.45 - 2,320.33 |
| 2,088.09 | 1,670.47 - 2,505.70 | ||
| 2,066.78 | 1,446.75 - 2,686.81 |
Overview of Glenmark Pharmaceuticals Limited
ISIN
INE935A01035
Industry
Drug Manufacturers - Specialty & Generic
Vol.Avg
1,298,110
Market Cap
601,793,632,500
Last Dividend
2.5
Official Website
IPO Date
2002-07-01
DCF Diff
3,736.13
DCF
-1,604
Financial Ratios Every Investor Needs
Stock Dividend of GLENMARK
| Date | Label | Adj Dividend | Dividend | Record Date | Payment Date | Declaration Date |
|---|---|---|---|---|---|---|
| 2025-09-15 | September 15, 25 | 2.5 | 2.5 | 2025-09-15 | 2025-10-01 | |
| 2024-09-13 | September 13, 24 | 2.5 | 2.5 | 2024-09-16 | 2024-10-27 | |
| 2023-09-18 | September 18, 23 | 2.5 | 2.5 | 2023-09-18 | 2023-10-29 | |
| 2022-09-12 | September 12, 22 | 2.5 | 2.5 | 2022-09-13 | 2022-10-27 | |
| 2021-09-08 | September 08, 21 | 2.5 | 2.5 | 2021-09-09 | 2021-10-24 |
Annual Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | R&D Expenses | G&A Expenses | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 13,435.46 Cr | 4,353.34 Cr | 5,460.33 Cr | 0.4064 | 0.00 Cr | 0.00 Cr | 1,865.37 Cr | 1,047.10 Cr | 37.11 | 2,092.28 Cr | 0.0779 |
| 2024-03-31 | 11,813.10 Cr | 8,553.82 Cr | 3,259.28 Cr | 0.2759 | 1,225.83 Cr | 263.11 Cr | 631.07 Cr | -1,501.67 Cr | -53.22 | 1,134.37 Cr | -0.1271 |
| 2023-03-31 | 11,583.24 Cr | 7,953.04 Cr | 3,630.20 Cr | 0.3134 | 1,250.04 Cr | 304.00 Cr | 1,078.87 Cr | 297.25 Cr | 10.53 | 1,158.05 Cr | 0.0257 |
| 2022-03-31 | 12,174.20 Cr | 8,065.46 Cr | 4,108.73 Cr | 0.3375 | 1,278.71 Cr | 400.70 Cr | 1,840.05 Cr | 941.71 Cr | 33.37 | 2,226.06 Cr | 0.0774 |
| 2021-03-31 | 10,806.03 Cr | 7,225.73 Cr | 3,580.29 Cr | 0.3313 | 1,318.69 Cr | 317.26 Cr | 1,716.04 Cr | 970.04 Cr | 34.38 | 2,179.14 Cr | 0.0898 |
Annual Financials Balance Sheet
| Date | C&C Equ. | Tot. Assets | Tot. Liab. | Stock. Equity | Tot. Debt | Net Debt | Inv. | PP&E (Net) | Curr. Def. Rev. | Non-Curr. Def. Rev. | LT Invest. | Curr. Liab. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 1,675.71 Cr | 16,049.55 Cr | 7,200.48 Cr | 8,849.4410 Cr | 2,472.67 Cr | 796.96 Cr | 3,028.53 Cr | 3,861.35 Cr | 0.00 Cr | 0.00 Cr | 56.36 Cr | 5,967.0240 Cr |
| 2024-03-31 | 1,658.27 Cr | 14,358.62 Cr | 6,511.08 Cr | 7,847.9270 Cr | 1,230.93 Cr | -427.34 Cr | 2,513.05 Cr | 3,537.48 Cr | 0.00 Cr | 0.00 Cr | 795.80 Cr | 5,818.5870 Cr |
| 2023-03-31 | 1,159.20 Cr | 19,371.68 Cr | 9,532.42 Cr | 9,473.9230 Cr | 4,607.88 Cr | 3,448.68 Cr | 2,373.62 Cr | 4,221.47 Cr | 0.00 Cr | 131.85 Cr | 47.28 Cr | 5,105.0560 Cr |
| 2022-03-31 | 1,410.53 Cr | 17,083.29 Cr | 7,645.17 Cr | 9,086.6470 Cr | 3,962.02 Cr | 2,551.50 Cr | 2,499.83 Cr | 4,653.55 Cr | 0.00 Cr | 121.32 Cr | 55.66 Cr | 4,689.4310 Cr |
| 2021-03-31 | 1,138.10 Cr | 15,603.58 Cr | 8,539.30 Cr | 7,064.6270 Cr | 4,985.72 Cr | 3,847.62 Cr | 2,276.83 Cr | 4,203.54 Cr | 4.39 Cr | 136.61 Cr | 51.90 Cr | 4,201.0200 Cr |
Annual Financials Cash Flow Statement
| Date | Operating Cash | Investing Cash | Financing Cash | Free Cash | Cash Change | Cash at End | CapEx | Income | Debt Repay | Dividends | Inventory |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | -827.5950 Cr | 2.0940 Cr | 787.0450 Cr | -1,577.1640 Cr | 17.4370 Cr | 1,675.7070 Cr | -750.7200 Cr | 1,399.2090 Cr | 1,200.5120 Cr | -70.4420 Cr | -450.8070 Cr |
| 2024-03-31 | -265.4440 Cr | 4,543.7300 Cr | -3,906.1270 Cr | -1,163.8220 Cr | 215.2440 Cr | 1,658.2700 Cr | -898.3780 Cr | -1,501.6680 Cr | -3,168.3670 Cr | -117.7520 Cr | -513.8580 Cr |
| 2023-03-31 | 625.3920 Cr | -528.4910 Cr | -77.4560 Cr | 17.6290 Cr | 32.5000 Cr | 1,443.0260 Cr | -607.7630 Cr | 868.4510 Cr | 629.9690 Cr | -136.6060 Cr | -375.1690 Cr |
| 2022-03-31 | 1,108.6520 Cr | -333.2800 Cr | -520.4910 Cr | 318.5350 Cr | 272.4310 Cr | 1,410.5260 Cr | -790.1170 Cr | 1,441.2460 Cr | -1,030.7970 Cr | -92.6950 Cr | -203.4190 Cr |
| 2021-03-31 | 1,131.2130 Cr | -675.2360 Cr | -441.7790 Cr | 356.4550 Cr | 27.8200 Cr | 1,138.0950 Cr | -774.7580 Cr | 1,382.4750 Cr | 18.9670 Cr | -70.4470 Cr | -133.8080 Cr |
Quarterly Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|
| 2025-06-30 | 3,059.33 Cr | 1,015.58 Cr | 2,043.76 Cr | 0.6680 | 450.59 Cr | 46.87 Cr | 1.66 | 283.73 Cr | 0.0153 |
| 2025-03-31 | 3,267.89 Cr | 1,088.95 Cr | 2,131.18 Cr | 0.6522 | 435.82 Cr | 4.65 Cr | 0.16 | 199.89 Cr | 0.0014 |
| 2024-12-31 | 3,301.90 Cr | 1,084.24 Cr | 2,217.67 Cr | 0.6716 | 477.49 Cr | 347.96 Cr | 12.33 | 631.36 Cr | 0.1054 |
| 2024-09-30 | 3,400.50 Cr | 1,070.08 Cr | 2,330.42 Cr | 0.6853 | 481.63 Cr | 354.21 Cr | 12.55 | 641.33 Cr | 0.1042 |
| 2024-06-30 | 3,244.19 Cr | 1,938.31 Cr | 1,305.88 Cr | 0.4025 | 470.42 Cr | 340.27 Cr | 12.06 | 619.71 Cr | 0.1049 |
Quarterly Financials Balance Sheet
| Date | Cash & Equiv. | Short-Term Inv. | Cash & Short-Term | Net Receivables | Inventory | Total Curr. Assets | PP&E (Net) | Total Assets | Total Liabilities |
|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 1,675.71 Cr | 91.97 Cr | 1,767.67 Cr | 3,341.95 Cr | 3,028.53 Cr | 9,295.47 Cr | 3,861.35 Cr | 16,049.55 Cr | 7,200.48 Cr |
| 2024-12-31 | 0.00 Cr | 0.00 Cr | 1,820.24 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -8,445.50 Cr |
| 2024-09-30 | 1,818.90 Cr | 221.80 Cr | 2,040.70 Cr | 2,863.43 Cr | 2,840.21 Cr | 9,033.48 Cr | 3,550.22 Cr | 15,235.34 Cr | 6,789.85 Cr |
| 2024-06-30 | 0.00 Cr | 0.00 Cr | 1,659.46 Cr | 0.00 Cr | 0.00 Cr | 1,659.46 Cr | 0.00 Cr | 0.00 Cr | -7,847.55 Cr |
| 2024-03-31 | 1,658.27 Cr | 12.13 Cr | 1,670.40 Cr | 1,858.41 Cr | 2,513.05 Cr | 7,428.08 Cr | 3,537.48 Cr | 14,358.62 Cr | 6,511.08 Cr |
Quarterly Financials Cash Flow Statement
| Date | Net Income | Operating Cash Flow | Investing Cash Flow | Financing Cash Flow | Net Cash Change | Cash at End | Cash at Beginning | CapEx | Free Cash Flow |
|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 4.65 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-12-31 | 347.96 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-09-30 | 354.21 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-06-30 | 340.27 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-03-31 | -1,218.28 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
Splits History
| Date | Label | Split Ratio |
|---|---|---|
| 2007-09-10 | September 10, 07 | 2:1 |
| 2005-03-04 | March 04, 05 | 2:1 |
| 2003-10-23 | October 23, 03 | 5:1 |
Similar Stocks: Drug Manufacturers - Specialty & Generic
| Company Name | Symbol | Price | Market Cap | Volume |
|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | SUNPHARMA | ₹1,616.60 | ₹3,878,676,048,000.00 | ₹1,878,887.00 |
| Divi's Laboratories Limited | DIVISLAB | ₹6,026.50 | ₹1,599,848,928,500.00 | ₹487,570.00 |
| Torrent Pharmaceuticals Limited | TORNTPHARM | ₹3,566.20 | ₹1,206,962,559,000.00 | ₹139,352.00 |
| Dr. Reddy's Laboratories Limited | DRREDDY | ₹1,316.70 | ₹1,095,964,560,653.00 | ₹1,042,670.00 |
| Mankind Pharma Limited | MANKIND | ₹2,579.60 | ₹1,064,750,578,074.00 | ₹181,489.00 |
| Zydus Lifesciences Limited | ZYDUSLIFE | ₹1,044.75 | ₹1,051,258,792,500.00 | ₹559,507.00 |
| Lupin Limited | LUPIN | ₹2,043.40 | ₹933,333,167,000.00 | ₹1,611,273.00 |
| Alkem Laboratories Limited | ALKEM | ₹5,448.00 | ₹651,390,120,000.00 | ₹120,660.00 |
| Aurobindo Pharma Limited | AUROPHARMA | ₹1,094.40 | ₹635,629,708,800.00 | ₹793,814.00 |
| Glenmark Pharmaceuticals Limited | GLENMARK | ₹2,132.50 | ₹601,793,632,500.00 | ₹615,366.00 |
| Laurus Labs Limited | LAURUSLABS | ₹896.05 | ₹483,710,191,250.00 | ₹1,298,692.00 |
| Suven Pharmaceuticals Limited | SUVENPHAR | ₹1,078.00 | ₹412,407,234,624.00 | ₹1,177,218.00 |
| Cohance Lifesciences Limited | COHANCE | ₹980.40 | ₹375,068,694,643.00 | ₹176,773.00 |
| Ipca Laboratories Limited | IPCALAB | ₹1,314.80 | ₹333,570,019,200.00 | ₹237,352.00 |
| Ajanta Pharma Limited | AJANTPHARM | ₹2,579.10 | ₹322,222,437,600.00 | ₹58,260.00 |
| J. B. Chemicals & Pharmaceuticals Limited | JBCHEPHARM | ₹1,699.90 | ₹266,197,540,400.00 | ₹56,240.00 |
| Wockhardt Limited | WOCKPHARMA | ₹1,518.00 | ₹246,651,927,918.00 | ₹287,476.00 |
| Piramal Enterprises Limited | PEL | ₹1,083.70 | ₹245,650,948,600.00 | ₹565,474.00 |
| Eris Lifesciences Limited | ERIS | ₹1,675.90 | ₹228,269,311,300.00 | ₹711,885.00 |
| AstraZeneca Pharma India Limited | ASTRAZEN | ₹9,003.50 | ₹225,087,500,000.00 | ₹7,058.00 |
| Neuland Laboratories Limited | NEULANDLAB | ₹16,049.00 | ₹205,907,065,100.00 | ₹157,007.00 |
| Alembic Pharmaceuticals Limited | APLLTD | ₹946.50 | ₹186,046,879,500.00 | ₹132,074.00 |
| Jubilant Pharmova Limited | JUBLPHARMA | ₹1,122.30 | ₹178,761,066,300.00 | ₹82,149.00 |
| Caplin Point Laboratories Limited | CAPLIPOINT | ₹2,245.60 | ₹170,691,873,520.00 | ₹78,387.00 |
| NATCO Pharma Limited | NATCOPHARM | ₹862.20 | ₹154,428,642,000.00 | ₹287,000.00 |
| Glenmark Life Sciences Limited | GLS | ₹1,086.00 | ₹133,070,838,000.00 | ₹130,938.00 |
| Granules India Limited | GRANULES | ₹534.35 | ₹129,656,821,400.00 | ₹1,274,862.00 |
| Procter & Gamble Health Limited | PGHL | ₹6,243.50 | ₹103,638,353,900.00 | ₹6,067.00 |
| Aarti Pharmalabs Limited | AARTIPHARM | ₹926.35 | ₹83,957,850,833.00 | ₹170,096.00 |
| Strides Pharma Science Limited | STAR | ₹909.75 | ₹83,854,113,825.00 | ₹182,119.00 |
| Shilpa Medicare Limited | SHILPAMED | ₹827.60 | ₹80,931,748,840.00 | ₹90,322.00 |
| FDC Limited | FDC | ₹463.35 | ₹75,438,013,500.00 | ₹27,055.00 |
| Innova Captab Limited | INNOVACAP | ₹859.60 | ₹49,190,549,828.00 | ₹33,571.00 |
| Suven Life Sciences Limited | SUVEN | ₹224.63 | ₹48,978,481,767.00 | ₹179,307.00 |
| Aarti Drugs Limited | AARTIDRUGS | ₹509.65 | ₹46,515,755,500.00 | ₹129,437.00 |
| Sun Pharma Advanced Research Company Limited | SPARC | ₹143.10 | ₹46,439,098,200.00 | ₹131,426.00 |
| Sequent Scientific Limited | SEQUENT | ₹182.51 | ₹45,688,640,850.00 | ₹212,635.00 |
| RPG Life Sciences Limited | RPGLIFE | ₹2,380.30 | ₹39,367,781,700.00 | ₹11,398.00 |
| Gufic Biosciences Limited | GUFICBIO | ₹369.25 | ₹37,027,651,500.00 | ₹37,782.00 |
| Orchid Pharma Limited | ORCHPHARMA | ₹710.75 | ₹36,048,600,325.00 | ₹42,599.00 |
| Unichem Laboratories Limited | UNICHEMLAB | ₹506.40 | ₹35,653,497,120.00 | ₹17,743.00 |
| IOL Chemicals and Pharmaceuticals Limited | IOLCP | ₹115.76 | ₹33,978,685,520.00 | ₹10,738,156.00 |
| Solara Active Pharma Sciences Limited | SOLARA | ₹677.55 | ₹32,626,065,150.00 | ₹56,274.00 |
| Hikal Limited | HIKAL | ₹257.45 | ₹31,743,842,450.00 | ₹240,530.00 |
| Morepen Laboratories Limited | MOREPENLAB | ₹53.90 | ₹29,534,720,600.00 | ₹3,571,211.00 |
| Indoco Remedies Limited | INDOCO | ₹299.05 | ₹27,586,734,495.00 | ₹342,407.00 |
| Alembic Limited | ALEMBICLTD | ₹103.16 | ₹26,489,631,017.00 | ₹256,891.00 |
Key Executives
President & Business Head of India Formulations
Mr. Alok Malik
Gender: male
Year Born:
President & Global Head of Formulation Operations
Mr. Brijlal Motwani
Gender: male
Year Born:
Executive Director
Mr. V. S. Mani
Gender: male
Year Born: 1965
President
Mr. Anurag Mantri
Gender: male
Year Born: 1971
President and Chief Human Resources Officer
Mr. Alind Sharma
Gender: male
Year Born: 1971
Executive Director of Corporate Services & Executive Director
Ms. Cherylann Maria Pinto B.Pharm
Gender: female
Year Born: 1967
Chairman, MD & Chief Executive Officer
Mr. Glenn Mario Saldanha
Gender: male
Year Born: 1970
Company Secretary & Compliance Officer
Mr. Harish Vinayak Kuber
Gender: male
Year Born:
President & Head of Global Pharmaceutical Development
Mr. Ulhas R. Dhuppad
Gender: male
Year Born: 1967
President & Chief Quality Officer
Mr. Indrajit Bose
Gender: male
Year Born:
FAQs about Glenmark Pharmaceuticals Limited
Who is the CEO of the company?
The CEO is Glenn Mario Saldanha.
What is the current market price of the stock?
The current price is ₹2,132.50.
What is the 52-week price range?
The range is ₹1275.5-2284.8.
What is the market capitalization of the company?
The market capitalization is ₹60,179.36 crores.
What is the Price-to-Earnings (P/E) ratio?
The P/E ratio is 79.89.
Which sector does the company belong to?
The company operates in the Healthcare sector.
What does the company do?
Overview of Glenmark Pharmaceuticals Limited (ISIN: INE935A01035) is a leading Drug Manufacturers - Specialty & Generic in India. With a market capitalization of ₹60,179.36 crores and an average daily volume of 1,298,110 shares, it operates in the Drug Manufacturers - Specialty & Generic. The company last declared a dividend of ₹2.5.